Search results
Analysts Are Updating Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Estimates After Its...
Simply Wall St. via Yahoo Finance· 2 years agoShareholders of Axsome Therapeutics, Inc. (NASDAQ:AXSM) will be pleased this week, given that the...
Analysts Just Made A Substantial Upgrade To Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasts
Simply Wall St. via Yahoo Finance· 1 year agoAxsome Therapeutics, Inc. (NASDAQ:AXSM) shareholders will have a reason to smile today, with the...
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
Zacks via Yahoo Finance· 2 years agoAxsome AXSM announced the enrollment of the first patient in the EMERGE phase III open label study...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 month agoAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript May 6, 2024 Axsome...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Is Expected To Breakeven In The Near Future
Simply Wall St. via Yahoo Finance· 10 months agoAxsome Therapeutics, Inc. (NASDAQ:AXSM) is possibly approaching a major achievement in its business,...
Insider Sell: COO Mark Jacobson Sells 24,662 Shares of Axsome Therapeutics Inc (AXSM)
GuruFocus.com via Yahoo Finance· 2 months agoAxsome Therapeutics Inc (NASDAQ:AXSM), a biopharmaceutical company focused on developing novel...
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Earnings Haven't Escaped The Attention Of Investors
Simply Wall St. via Yahoo Finance· 9 months agoAxsome Therapeutics, Inc.'s (NASDAQ:AXSM) price-to-sales (or "P/S") ratio of 19.3x may look like a...
Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss
Zacks via Yahoo Finance· 10 months agoNektar Therapeutics NKTR reported a loss of 27 cents per share for the second quarter of 2023, which...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting...
Simply Wall St. via Yahoo Finance· 4 weeks agoInvestors in Axsome Therapeutics, Inc. (NASDAQ:AXSM) had a good week, as its shares rose 2.0% to...
Axsome Therapeutics Inc (AXSM) Reports Robust Revenue Growth in Q4 and Full Year 2023
GuruFocus.com via Yahoo Finance· 3 months agoNet Product Revenue: Q4 revenue of $71.5 million and full-year revenue of $204.9 million, marking...